Global burden of paediatric vision impairment: a trend analysis from 1990 to 2017

Abstract

Learning Objectives: Upon completion of this activity, participants will: 1.Describe DALYs caused by paediatric vision impairment in different age groups by socioeconomic indicators and other factors in 2017, according to a retrospective analysis of GBD data.2.Determine the trend from 1990 to 2017 in DALYs caused by paediatric vision impairment in different age groups, according to a retrospective analysis of GBD data.3.Identify clinical and public health implications of findings regarding DALYs caused by paediatric vision impairment in different age groups, according to a retrospective analysis of GBD data. Continuing Medical Education: In support of improving patient care, this activity has been planned and implemented by Medscape, LLC and Springer Nature. Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Medscape, LLC designates this Journal-based CME activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Credit hours: 1.0 Expiration date: Release date: Post-test link:https://medscape.org/eye/posttest949866[InlineMediaObject not available: see fulltext.] Authors/Editors disclosure information: Sobha Sivaprasad, MD, has disclosed the following relevant financial relationships: Served as an advisor or consultant for: Allergan, Inc.; Apellis Pharmaceuticals; Bayer AG; Boehringer Ingelheim Pharmaceuticals, Inc.; Heidelberg Pharma GmbH; Novartis Pharmaceuticals Corporation; Oculis; Optos; Oxurion NV; Roche. Served as a speaker or a member of a speakers bureau for: Allergan, Inc.; Bayer AG; Novartis Pharmaceuticals Corporation; Optos. Received grants for clinical research from: Allergan, Inc.; Bayer AG; Boehringer Ingelheim Pharmaceuticals, Inc.; Novartis Pharmaceuticals Corporation; Optos. Parya Abdolalizadeh, MD, MPH, disclosed has no relevant financial relationships. Samira Chaibakhsh, PhD, disclosed has no relevant financial relationships. Khalil Ghasemi Falavarjani, MD, disclosed has no relevant financial relationships.